All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Lipids secreted from Meibomian glands are considered the main component of the superficial lipid layer of the tear film that protects the aqueous phase from evaporation and stabilizes the tear film by lowering surface tension \[[@pone.0185603.ref001],[@pone.0185603.ref002]\]. It has been suggested that when the Meibomian glands become atrophied, keratinized, obstructed, or otherwise compromised to yield reduced or altered meibum in Meibomian gland dysfunction (MGD), these changes can result in a less stable tear film leading to increased aqueous evaporation rate \[[@pone.0185603.ref003]--[@pone.0185603.ref005]\]. Despite signs and symptoms being poorly correlated, it is believed that tear film instability can lead to a vicious cycle of tear hyperosmolarity and inflammation, ultimately resulting in adverse symptoms \[[@pone.0185603.ref005]\].

Studies have reported that Meibomian gland atrophy was associated with thinner tear lipid layer \[[@pone.0185603.ref006]--[@pone.0185603.ref010]\]. Of these studies, only one reports significant relationships between shorter tear breakup time and either thinner tear lipid layers or increased symptoms\[[@pone.0185603.ref010]\]. These discrepancies do not provide convincing evidence that alterations in the oil glands will be reflected downstream in tear film stability or symptoms. Conflicting results could be due to differences in study population, sample size, or instrumentation. Furthermore, these studies did not control for potential confounders in their analyses \[[@pone.0185603.ref006]--[@pone.0185603.ref010]\]. Both endogenous factors, such as age and sex, as well as exogenous factors, such as medications (e.g., hormonal birth control (HBC), anti-allergy, and antidepressants) and contact lenses are believed to influence one or many of the abovementioned ocular surface parameters \[[@pone.0185603.ref005],[@pone.0185603.ref011]\].

This cross-sectional study aimed to determine the risk factors in a young adult population for severe Meibomian gland atrophy by accounting for various endogenous (e.g., age, sex) and exogenous (e.g., tobacco, medications, contact lens use) factors. The secondary aim was to investigate the potential downstream impact of severe Meibomian gland atrophy by evaluating relationships between severe Meibomian gland atrophy and tear lipid layer thickness, between tear lipid layer thickness and tear breakup time, and between tear breakup time and ocular dryness symptoms, while controlling for potential confounders. The results may help to identify individuals who are at greater risk of having severe Meibomian gland atrophy and to elucidate the overall impact of severe Meibomian gland atrophy on other ocular surface parameters.

Methods {#sec006}
=======

Subjects {#sec007}
--------

This was a cross-sectional study conducted at the University of California, Berkeley (UCB), Clinical Research Center. Study participants, who included non-contact lens and contact lens users, were recruited from the UCB campus and surrounding community. Subjects were required to have no history of ocular surgery or any active ocular inflammation or infection. Contact lens users were required to discontinue wearing their lenses 24 hours prior to their scheduled visits, and all participants were asked not to apply eye makeup on the day of their appointments. Written informed consent was obtained from all study participants, and the study adhered to the tenets of the Declaration of Helsinki. The study protocol was approved by the UCB Committee for Protection of Human Subjects.

Sample size estimates were calculated with two formulas \[[@pone.0185603.ref012],[@pone.0185603.ref013]\] for the dichotomous outcome and one \[[@pone.0185603.ref014]\] for the continuous outcomes, using previously published population estimates for the main outcome severe Meibomian gland atrophy \[[@pone.0185603.ref015],[@pone.0185603.ref016]\], and for the secondary outcomes tear lipid layer thickness \[[@pone.0185603.ref016],[@pone.0185603.ref017]\], non-invasive tear breakup time \[[@pone.0185603.ref017],[@pone.0185603.ref018]\], fluorescein tear breakup time \[[@pone.0185603.ref017]--[@pone.0185603.ref019]\], and SPEED score \[[@pone.0185603.ref017],[@pone.0185603.ref020]\]. The highest sample size estimate for the main outcome of severe Meibomian gland atrophy, derived from the formula by Peduzzi, et al. \[[@pone.0185603.ref012]\], and from population estimates of severe Meibomian gland atrophy by Napoli, et al. \[[@pone.0185603.ref015]\], was 55 subjects in order to detect 3:1 odds of having severe Meibomian gland atrophy with 5% two-sided level of significance and 80% statistical power. The highest estimate among all outcomes was for fluorescein tear breakup time using the formula from Charan, et al. \[[@pone.0185603.ref014]\] and population estimates from Yeh, et al. \[[@pone.0185603.ref018]\] suggesting a sample size of 101 subjects to detect a minimum of a five-second difference in tear breakup time with 5% two-sided level of significance and 80% statistical power.

Measurements and procedures {#sec008}
---------------------------

[Table 1](#pone.0185603.t001){ref-type="table"} lists all study procedures administered in this study in the order in which they were conducted, including references if methods were previously published. After providing written informed consent, study participants completed the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire \[[@pone.0185603.ref021]\] and the health history form, which requested information pertaining to current use of tobacco products, eye drops, medications (allergy, HBC, anti-depressives), eye makeup, and contact lenses.

10.1371/journal.pone.0185603.t001

###### Study procedures listed in order performed.

![](pone.0185603.t001){#pone.0185603.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Order   Procedure                                                          Equipment/Materials                                                                          Measurements
  ------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  1       Ocular and Medical History                                         Ocular and Medical History Form                                                              • Contact Lens History (Use, duration, frequency)\
                                                                                                                                                                          • Current Medications (Yes/No)

  2       Symptoms Assessment                                                Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire\[[@pone.0185603.ref021]\]   • Severity Score (0--12)\
                                                                                                                                                                          • Frequency Score (0--12)\
                                                                                                                                                                          • Total Score (0--24)

  3       Tear Film Interferometry and Number of Partial & Complete Blinks   Lipiview (TearScience, Morrisville, NC, USA)                                                 • Average Lipid Layer Thickness (nm)\
                                                                                                                                                                          • Number of Partial Blinks\
                                                                                                                                                                          • Total Number of Blinks

  4       Manual Non-invasive Tear Breakup Time (NITBUT)                     Medmont Corneal Topographer E300 (Medmont Pty Ltd; Australia)                                Tear Breakup Time (sec)

  5       Anatomical Assessment                                              • Penlight\                                                                                  • Lagophthalmos (Yes/No)\
                                                                             • SL 120 (Carl Zeiss Meditec, Germany)                                                       • Palpebral Aperture Size (mm)

  6       Tear Breakup Time with fluorescein (FTBUT)                         BioGlo™ Strip, Unisol Non-Preserved Saline                                                   Tear Breakup Time (sec)

  7       Corneal Staining                                                   BioGlo™ Strips, Unisol Non-Preserved Saline                                                  Sjogren's International Clinical Collaborative Alliance (SICCA): Overall Score (0--4)\[[@pone.0185603.ref022]\]

  8       Meibomian Gland Expressibility                                     Korb Meibomian Gland Evaluator™ (TearScience®; North Carolina)                               Total Quality Score (0--45) and Quantity Score (0--45) recorded for each upper and lower lids \[[@pone.0185603.ref017],[@pone.0185603.ref023]\]

  9       Conjunctival Staining                                              1% Lissamine Green / 2% Sodium fluorescein ophthalmic drops                                  SICCA Score (0--3) per quadrant \[[@pone.0185603.ref022]\]

  10      Line of Marx                                                       1% Lissamine Green / 2% Sodium fluorescein ophthalmic drops                                  Score (0--3) was marked for each upper and lower lids \[[@pone.0185603.ref024]\]

  11      Lid Wiper Epitheliopathy                                           1% Lissamine Green / 2% Sodium fluorescein ophthalmic drops                                  • Length Score (0--3)\[[@pone.0185603.ref025]\]\
                                                                                                                                                                          • Sagittal Width Score (0--3)\[[@pone.0185603.ref025]\]

  12      Meibography                                                        Oculus Keratograph 5M (Oculus, Inc.; Arlington, WA, USA)                                     • Meiboscore (0--3) \[[@pone.0185603.ref026]\]\
                                                                                                                                                                          • No. of Total Glands\
                                                                                                                                                                          • No. of Atrophied Glands\
                                                                                                                                                                          • No. of Tortuous Glands
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next were clinical measurements, which were taken on both eyes, always starting with the right eye. The clinical tests were ordered from least to most invasive, aimed at minimizing the impact of each test on subsequent tests. Details that could not be provided in the table are discussed below.

Performed first were non-invasive procedures that did not involve lid manipulation or instillation of drops, which included tear lipid layer thickness, non-invasive tear breakup time, and slit lamp examination with white light. The Lipiview® instrument (TearScience®; North Carolina, USA) measured tear lipid layer thickness (1 ICU unit \~ 1 nanometer) by conducting an interferometric color assessment of the tear film based on specular reflection, and it also measured the number of partial and total blinks within the 20-second measurement period. Participants were instructed to fixate on a light target while blinking normally during the measurement period. Non-invasive tear breakup time (NITBUT; seconds) was measured subjectively by the investigator with a Placido-disc-based corneal topographer (Medmont E300; Medmont Pty Ltd; Australia) three times per eye, alternating between eyes.

Next, the invasive procedures were performed. Tear breakup time with sodium fluorescein (FTBUT; seconds) using BioGlo™ strips wetted with Unisol non-preserved saline were measured three times per eye, alternating between eyes. Corneal staining was scored immediately after FTBUT measurements on the SICCA scale \[[@pone.0185603.ref022]\]. Meibomian gland expression was then performed on the lateral, central, and medial regions of the lower and upper eyelid margins with a Korb Meibomian Gland Evaluator™. This procedure involved applying 10--15 seconds of gentle pressure on the skin inferior to the lower eyelid margin while the participant was in upgaze and superior to the upper eyelid margin while the participant was in downgaze. The secretions were scored based on quality and quantity \[[@pone.0185603.ref017],[@pone.0185603.ref023]\]. Next, 1% lissamine green/2% fluorescein combination ophthalmic solution was instilled to assess conjunctival staining using the SICCA scale \[[@pone.0185603.ref022]\] and positioning of Marx's line with respect to Meibomian gland orifices using the scale defined by Yamaguchi, et al. \[[@pone.0185603.ref024]\] Five minutes later, a second instillation of the lissamine green/fluorescein combination drop was instilled to assess length and width of lid wiper epitheliopathy after everting the upper eyelid using the scale previously defined by Korb, et al. \[[@pone.0185603.ref025]\] Finally, meibography images of both the upper and lower lids were scored based on the estimated percent area of Meibomian gland atrophy using Arita's meiboscore scale \[[@pone.0185603.ref026]\] and evaluated for presence of tortuous Meibomian glands (bending ≥ 45°) and total number of visible Meibomian glands per eyelid ([Fig 1](#pone.0185603.g001){ref-type="fig"}).

![Meibomian gland characteristics.\
(A) Typical Meibomian gland orientation with glands running parallel and the full length of the eyelid, (B) Meibomian gland atrophy represented by shortened glands and trailing "empty" space, and (C) Meibomian gland tortuosity represented by glands with sharp bends (≥ 45°) or curly/hook appearances. Images courtesy of the Clinical Research Center, University of California, Berkeley.](pone.0185603.g001){#pone.0185603.g001}

Statistical methods {#sec009}
-------------------

The main outcome of interest was a binary variable representing presence/absence of severe Meibomian gland atrophy, where Meiboscore = 3 represents severe atrophy and Meiboscore\<3 represents non-severe atrophy. The secondary outcomes were tear lipid layer thickness, tear breakup times, and SPEED score. Tear breakup times were transformed by natural logarithm to better approximate normality for statistical tests. Since both measures of tear breakup time (NITBUT and FTBUT) were moderately correlated (Pearson correlation = 0.53, p\<0.001), multivariable models included only one of the measures at a time.

Analysis to examine direct, physiologically plausible relationships among the data collected was conducted using logistic regression for the binary outcome presence/absence of severe Meibomian gland atrophy, linear regression for the continuous outcomes tear lipid layer thickness and SPEED score, and log-linear regression for the log-transformed outcomes NITBUT and FTBUT. All regression models used the Huber-White standard error estimator clustered by subject (Stata/IC 14.0; vce(cluster) option) to account for within-subject correlations between eyes.

In the exploratory analysis, robust (clustered) regression models (1 dependent: 1 independent variable) were built for each direct, physiologically plausible relationship using the models as described above. Preliminary multivariable models (1 dependent: multiple independent variables) were then built for each outcome to include all significant independent variables from the respective exploratory analysis. Final models were selected by considering F-test p-values and testing assumptions using residual and other diagnostic plots and diagnostic tests, including Hosmer-Lemeshow.

Similar to the exploratory analysis, post-hoc comparison of ocular surface parameters between contact lens and non-contact lens users also used logistic regression for binary dependent variables and linear regression for continuous dependent variables, again, using the Huber-White standard error estimator clustered by subject (Stata/IC 14.0; vce(cluster) option) to account for within-subject correlations between eyes. In all of these models, the diagnostic tests were treated as dependent variables and contact lens use was treated as a binary independent variable.

Results {#sec010}
=======

One hundred one (101) subjects (202 eyes) between 18 and 41 years of age (mean±SD = 22.3±4.0) completed the study. [Table 2](#pone.0185603.t002){ref-type="table"} describes the population demographics and their reported use of various products that may interfere with ocular surface health, and [Table 3](#pone.0185603.t003){ref-type="table"} shows study population means for the study outcome variables.

10.1371/journal.pone.0185603.t002

###### Demographics and product usage based on subject medical history \[N = 101 (202 eyes)\].
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  Characteristic                     No. of Subjects
  ---------------------------------- -----------------
  Sex                                
  *Female*                           71
  *Male*                             30
  Race                               
  *Asian*                            55
  *Non-Asian (White*, *Hispanics)*   29
  *Other*                            17
  Contact Lens Status                
  *Non-Users*                        50
  *Users*                            51
  Tobacco                            
  *Non-Users*                        97
  *Users*                            4
  Eye Drops                          
  *Non-Users*                        79
  *Users*                            22
  Allergy Medication                 
  *Non-Users*                        98
  *Users*                            3
  Hormonal Birth Control (HBC)       
  *\[Females only\]*                 
  *Non-Users*                        53
  *Users*                            18
  Anti-Depression Medication         
  *Non-Users*                        98
  *Users*                            3
  Make-Up Frequency                  
  *Never/Rarely*                     61
  *Frequently*                       21
  *Daily*                            19

10.1371/journal.pone.0185603.t003

###### Study distribution and means for main (severe Meibomian gland atrophy) and secondary outcomes.

SD = Standard deviation, SPEED = Subjective Patient Evaluation of Eye Dryness.
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                                             \# of Eyes   Mean (SD)
  ------------------------------------------ ------------ --------------
  **Any Severe Meibomian Gland Atrophy**                  
  **Not Present (Meiboscore\<3)**            185          
  **Present (Meiboscore = 3)**               17           
  **Tear Lipid Layer Thickness (nm)**                     59.7 (16.7)
  **Non-invasive Tear Breakup Time (sec)**                10.71 (5.68)
  **Fluorescein Tear Breakup Time (sec)**                 5.90 (4.25)
  **SPEED Score**                                         5.5 (4.1)

[Table 4](#pone.0185603.t004){ref-type="table"} is a summary of exploratory analysis for outcomes listed by columns and independent variables listed by rows. Relationships considered were ones in which the outcome and independent variable are believed to have a direct and physiologically plausible relationship. Intercepts, effect sizes, and P-values are listed for each relationship explored, with the significant relationships marked in bold, and relationships that were not examined for reasons described above are marked with a dash. Significant risk factors from exploratory analysis were included in the initial multivariable model for the respective outcome variable, and the final model was determined as described previously.

10.1371/journal.pone.0185603.t004

###### Exploratory analysis results for each direct, physiologically plausible relationship between a potential risk factor (rows) and an outcome variable (columns).
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  Risk Factors                      Outcomes                                                                                                                                                  
  --------------------------------- ---------- ---------- ----------- ------- ------------ ------------- ------ ----------- ------------- ------- ----------- ------------- ------ ---------- -------------
  Age                               0.03       1.05       0.246       78.25   **-0.83**    **0.032**     2.24   -0.00       0.990         2.13    -0.02       0.061         3.19   0.11       0.369
  Sex                               0.11       0.48       0.384       59.27   1.45         0.664         2.23   0.01        0.922         1.54    0.13        0.326         6.00   -1.57      0.068
  Race                                                                                                                                                                                        
  *Asian vs*. *Non-Asian*           0.08       1.47       0.587       59.39   2.75         0.447         2.15   **0.21**    **0.047**     1.51    0.17        0.217         5.45   -0.32      0.737
  Contact Lens Years                0.05       **1.11**   **0.050**   63.18   **-0.84**    **0.005**     2.34   **-0.03**   **0.002**     1.71    **-0.03**   **0.001**     4.91   0.15       0.086
  Tobacco Use                       0.08       3.98       0.252       59.47   5.78         0.443         2.24   -0.18       0.634         1.58    0.04        0.868         5.60   -1.85      0.099
  Eye Drop Use                      0.08       1.56       0.544       61.79   **-9.61**    **0.002**     2.29   **-0.24**   **0.011**     1.62    -0.17       0.196         4.49   **4.78**   **\<0.001**
  Allergy Medication Use            0.08       6.03       0.158       60.32   **-20.82**   **\<0.001**   2.24   0.01        0.984         1.58    -0.12       0.655         5.47   2.20       0.542
  Anti-depression Medication Use    ^+^        ^+^        ^+^         59.51   6.32         0.525         2.24   -0.07       0.773         1.58    -0.11       0.621         5.40   4.60       0.185
  Hormonal Birth Control Category                                             **-**                                                                                                           
  *FHBC*^*-*^ *vs*. *FHBC*          0.06       **4.76**   **0.028**   62.64   **13.30**    **\<0.001**   2.25   -0.05       0.707         1.58    -0.15       0.403         5.81   0.74       0.496
  *FHBC*^*-*^ *vs*. *Males*         0.88       0.885      -1.92       0.582   -0.00        0.990         0.09   0.492       -1.38         0.132                                               
  Make-Up Frequency                                                                                                                                                                           
  *Never/Rare vs*. *Frequent*       0.06       2.22       0.320       59.26   0.76         0.851         2.22   0.17        0.119         1.53    0.16        0.196         5.59   0.22       0.832
  *Never/Rare vs*. *Daily*          2.49       0.215      1.47        0.710   -0.11        0.320         0.08   0.618       -0.54         0.619                                               
  Meibomian Gland                                                                                                                                                                             ---
  *Any Severe Atrophy*              \-         **-**      **-**       60.35   **-16.35**   **0.032**     \-     \-          \-            \-      \-          \-            \-     \-         \-
  *Any Tortuosity*                  \-         **-**      **-**       59.21   0.75         0.785         \-     \-          \-            \-      \-          \-            \-     \-         \-
  *Total Expressibility*            \-         **-**      **-**       59.48   0.01         0.954         \-     \-          \-            \-      \-          \-            \-     \-         \-
  Line of Marx Position                                                                                                                                                                       
  *Upper Eyelid*                    \-         \-         \-          59.88   -0.31        0.880         \-     \-          \-            \-      \-          \-            \-     \-         \-
  *Lower Eyelid*                    \-         \-         \-          58.93   0.82         0.650         \-     \-          \-            \-      \-          \-            \-     \-         \-
  Number of Blinks                                                                                                                                                                            
  *Total*                           \-         \-         \-          62.86   -0.49        0.288         2.44   **-0.03**   **0.001**     1.72    -0.02       0.163         \-     \-         \-
  *All Partial*                     \-         \-         \-          56.50   **7.44**     **0.005**     2.11   **0.30**    **0.001**     1.40    **0.41**    **\<0.001**   \-     \-         \-
  TLL Thickness                     \-         \-         \-          \-      \-           \-            2.05   0.00        0.219         1.06    **0.01**    **0.007**     \-     \-         \-
  Lagophthalmos                     \-         \-         \-          \-      \-           \-            2.21   0.22        0.094         1.56    0.18        0.168         \-     \-         \-
  Palpebral Aperture Size (mm)      \-         \-         \-          \-      \-           **-**         1.52   **0.07**    **0.030**     1.51    0.01        0.854         \-     \-         \-
  Cornea SICCA Score                \-         \-         \-          \-      \-           \-            2.28   -0.04       0.355         1.63    -0.05       0.277         \-     \-         \-
  Conjunctival Total SICCA Score    \-         \-         \-          \-      \-           **-**         2.34   **-0.08**   **\<0.001**   1.62    -0.03       0.263         \-     \-         \-
  NITBUT (sec)                      \-         \-         \-          \-      \-           \-            \-     \-          \-            \-      \-          \-            8.08   -1.14      0.098
  FTBUT (sec)                       \-         \-         \-          \-      \-           \-            \-     \-          \-            \-      \-          \-            6.32   -0.47      0.530
  Lid Wiper                                                                                                                                                                                   
  *Length*                          \-         \-         \-          \-      \-           \-            \-     \-          \-            \-      \-          \-            5.77   -0.28      0.306
  *Sagittal Width*                  \-         \-         \-          \-      \-           \-            \-     \-          \-            \-      \-          \-            5.83   -0.52      0.065

^A^ Robust logistic regression using Huber-White standard error estimator clustered by Subject ID; Odds ratio coefficient

^B^ Robust linear regression using Huber-White standard error estimator clustered by Subject ID

^C^ Robust log linear regression using Huber-White standard error estimator clustered by Subject ID

MG: Meibomian gland; TLL: Tear lipid layer; NITBUT: Non-invasive tear breakup time; FTBUT: Fluorescein tear breakup time; Int: Intercept; FHBC^-^: Females not using HBC; FHBC^+^: Females using HBC

^+^ No participants taking anti-depression medication had severe Meibomian gland atrophy

\- Relationship not evaluated because indirect association or not physiologically plausible

**BOLD** values represent significant P-values

To allow for comparisons among males and both female groups (users and non-users of HBC), we generated a categorical variable called HBC Category, which included three groups: female HBC non-users, female HBC users, and males.

Meibomian gland atrophy {#sec011}
-----------------------

In the study population, severe Meibomian gland atrophy was absent in 185 eyes and present in 17 eyes. Although both contact lens years and HBC Category were each significantly associated with Meibomian gland atrophy ([Table 5](#pone.0185603.t005){ref-type="table"}), contact lens years was no longer significant (p = 0.080) in the multivariable model when both variables were included. As a result, the best model for severe Meibomian gland atrophy ([Table 5](#pone.0185603.t005){ref-type="table"}) included only HBC Category as a risk factor. This model suggested that the odds of having severe Meibomian gland atrophy was 4.8 times greater for female HBC users than female HBC non-users (p = 0.028, 95% CI: \[1.2, 19.1\]) and that Meibomian gland atrophy severity was similar between female HBC non-users and males (p = 0.885, 95% CI: \[0.2, 5.1\]). [Table 6](#pone.0185603.t006){ref-type="table"} shows the distribution of eyes with severe Meibomian gland atrophy among the three HBC Category groups.

10.1371/journal.pone.0185603.t005

###### Logistic regression model for severe Meibomian gland atrophy.
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  EFFECT                            Severe Meibomian Gland Atrophy             
  --------------------------------- -------------------------------- --------- -------------
  **Intercept**                     0.06                             \<0.001   0.02, 0.15
  **HBC Category**                                                             
  **(Control: Female Non-Users)**                                              
  **Female Users**                  4.76                             0.028     1.19, 19.13
  **Males**                         0.88                             0.885     0.15, 5.14

Confidence Interval (CI).

10.1371/journal.pone.0185603.t006

###### Number of eyes with severe Meibomian gland atrophy (SMGA) among the hormonal birth control (HBC) groups.
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                     HBC Category   Total        
  ------------------ -------------- ------- ---- -----
  **SMGA Absent**    100            28      57   185
  **SMGA Present**   6              8       3    17
  **Total**          106            36      60   202

Female Non-Users of HBC (FHBC^-^); Female Users of HBC (FHBC^+^).

Tear lipid layer thickness {#sec012}
--------------------------

With average tear lipid layer thickness measured from the LipiView® as the outcome, we found the best multivariable model was one that included years of contact lens use, partial blinking pattern, and the interaction between severe Meibomian gland atrophy and HBC Category ([Table 7](#pone.0185603.t007){ref-type="table"}). The model suggested that tear lipid layer is 5 nm thinner for every 10 years of contact lens use (p = 0.032, 95% CI:\[-1.0, -0.01\]) and 6 nm thicker among all-partial blinkers compared to those who blink completely some or all the time (p = 0.033, 95% CI:\[0.5, 10.5\]). The model also suggests that female HBC users, regardless of their Meibomian gland atrophy status, had significantly thinner tear lipid layer than female HBC non-users who did not have severe Meibomian gland atrophy. Compared to female HBC non-users without severe Meibomian gland atrophy, tear lipid layer is thinner by approximately 10 nm for female HBC users without severe Meibomian gland atrophy (p = 0.007, 95% CI:\[-16.5, -2.7\]) and 21 nm thinner for female HBC users with severe Meibomian gland atrophy (p\<0.001, 95% CI:\[-28.0, -14.1\]). In general, tear lipid layer thickness for males was similar to female HBC non-users, regardless of Meibomian gland atrophy severity. [Fig 2](#pone.0185603.g002){ref-type="fig"} illustrates how tear lipid layer thickness varied with Meibomian gland atrophy severity across the three HBC groups.

![Tear film lipid layer thickness vs. Meiboscore, stratified by hormonal birth control use category.\
(A) Upper eyelid and (B) Lower eyelid. Meibomian gland atrophy severity based on Arita's meiboscore \[[@pone.0185603.ref026]\] (0 = None (0% atrophy), 1 = Mild (up to 33%), 2 = Moderate (33--66%), 3 = Severe (\>66%)). HBC: Hormonal birth control; FHBC^-^: Females not using HBC; FHBC^+^: Females using HBC.](pone.0185603.g002){#pone.0185603.g002}

10.1371/journal.pone.0185603.t007

###### Linear regression model for tear lipid layer thickness.
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  EFFECT                                        Tear Lipid Layer Thickness                           
  --------------------------------------------- ---------------------------- --------- ------------- --------------
  **Intercept**                                 62.9                         \<0.001   57.7, 68.0    
  **Contact Lens Years**                        -0.5                         0.032     -1.0, -0.01   
  **All Partial Blinks**                        5.5                          0.033     0.5, 10.5     
  **SMGA x HBC Category**                                                                            
  **(Control: SMGA Absent, FHBC**^**-**^**)**                                                        
  **SMGA Absent**                               **FHBC**^**+**^              -9.6      0.007         -16.5, -2.7
  **SMGA Absent**                               **Males**                    -3.7      0.272         -10.3, 2.9
  **SMGA Present**                              **FHBC**^**-**^              -5.8      0.552         -25.1, 13.5
  **SMGA Present**                              **FHBC**^**+**^              -21.0     \<0.001       -28.0, -14.1
  **SMGA Present**                              **Males**                    5.5       0.524         -11.5, 22.4

Confidence Interval (CI); Hormonal Birth Control (HBC); Severe Meibomian Gland Atrophy (SMGA); Female Non-Users of HBC (FHBC^-^); Female Users of HBC (FHBC^+^).

Tear film stability {#sec013}
-------------------

### FTBUT {#sec014}

The best multivariable model for ln(FTBUT) included tear lipid layer thickness and years of contact lens use ([Table 8](#pone.0185603.t008){ref-type="table"}). Although shorter FTBUT was significantly associated with all or some complete blinking in the exploratory analysis, it is also considered a collider because it is an effect of both the exposure (tear lipid layer thickness) and outcome (FTBUT) and can alter their true relationship if included in the model. Therefore, blinking status was not included in the model. The final model estimates that FTBUT will increase by 7% for every 10 nm increase in tear lipid layer thickness (p = 0.026, 95% CI: \[0.00, 0.01\]) and decrease by 12% for every 5 years of contact lens use (p = 0.004, 95% CI: \[-0.04, -0.01\]). A tear lipid layer thickness change from 60 nm to 40 nm decreases FTBUT from 5.4 sec to 4.7 sec for non-contact lens users and from 4.8 sec to 4.2 sec for those with 5 years of contact lens wear, neither of which is clinically significant.

10.1371/journal.pone.0185603.t008

###### Linear regression models for the log-transformed tear film stability measures.

![](pone.0185603.t008){#pone.0185603.t008g}

                                        ln(FTBUT)   ln(NITBUT)                                       
  ------------------------------------- ----------- ------------ ---------------- -------- --------- ----------------
  **Intercept**                         1.291       \<0.001      0.904, 1.678     2.283    \<0.001   1.966, 2.600
  **Tear Lipid Layer Thickness (nm)**   0.007       0.026        0.001, 0.013     0.002    0.349     -0.003, 0.007
  **Contact Lens Years**                -0.026      0.004        -0.043, -0.008   -0.021   0.015     -0.038, -0.004
  **Conjunctival SICCA Score**          \-          \-           \-               -0.073   0.002     -0.118, -0.027

Tear breakup time with fluorescein (FTBUT); non-invasive tear breakup time (NITBUT); Confidence Interval (CI).

### NITBUT {#sec015}

As indicated in [Table 4](#pone.0185603.t004){ref-type="table"}, NITBUT was significantly associated with several parameters in the univariate analysis but not with tear lipid layer thickness, which would be a more likely relationship. Without including blinking pattern for the same reason previously discussed, the best multivariable model suggested that shorter NITBUT on a long-transformed scale was not significantly associated with tear lipid layer thickness (p = 0.349) but that it was significantly associated with increased years of contact lens use (p = 0.015, 95% CI:\[-0.038, -0.004\]) and higher total conjunctival staining score (p = 0.002, 95% CI:\[-0.118, -0.027\]), which was largely driven by the nasal and temporal regions ([Table 8](#pone.0185603.t008){ref-type="table"}). While a single unit change in conjunctival staining score resulted in less than a second change in NITBUT (clinically insignificant), a contact lens user of 10 years was estimated to have 2 seconds shorter NITBUT than a non-user.

### Symptoms {#sec016}

Finally, of the potential risk factors for ocular dryness symptoms based on the SPEED score, univariable analysis revealed that symptoms were not significantly associated with FTBUT (p = 0.530) or NITBUT (p = 0.098). Instead, symptoms were strongly associated with eye drop use, such that the mean SPEED score was estimated to be 4.8 units higher for eye drop users than non-users (p\<0.001).

Post-hoc analysis: ocular surface differences between non-users and users of contact lenses {#sec017}
-------------------------------------------------------------------------------------------

In relation to Meibomian gland atrophy, there was no significant difference between contact lens users and non-users when comparing the relative number of cases with severe Meibomian gland atrophy (p = 0.164) ([Table 9](#pone.0185603.t009){ref-type="table"}). However, contact lens users were less likely to have any MG tortuosity in either the upper or lower eyelid (p = 0.031), and they had significantly shorter NITBUT (p = 0.009), reduced total Meibomian gland expressibility (p = 0.019), and higher SPEED scores (p = 0.002). Contact lens users had more partial (p = 0.012) and total blinks (p\<0.001) per 20-second measurement period compared to non-users. There was no difference in tear lipid layer thickness or FTBUT between non-users and users of contact lenses.

10.1371/journal.pone.0185603.t009

###### Comparison of diagnostic characteristics between non-contact lens and contact lens users.

![](pone.0185603.t009){#pone.0185603.t009g}

                                                Non-Contact Lens     Contact Lens   P-value
  --------------------------------------------- -------------------- -------------- ---------------------------------------------------
  Tear Lipid Layer Thickness (nm)               61(17)               55(16)         0.112[^1^](#t009fn001){ref-type="table-fn"}
  Non-invasive Tear Breakup Time (sec)          11.8(5.7)            9.3(4.7)       **0.009**[^1^](#t009fn001){ref-type="table-fn"}
  Fluorescein Tear Breakup Time (sec)           5.9(3.5)             5.6(5.1)       0.110[^1^](#t009fn001){ref-type="table-fn"}
  Meibomian Gland Expressibility Total          40 (13)              34(14)         **0.019**[^1^](#t009fn001){ref-type="table-fn"}
  SPEED Score                                   4 (3)                7 (4)          **0.002**[^1^](#t009fn001){ref-type="table-fn"}
  Number of Partial Blinks                      3.9 (2.8)            5.5 (4.0)      **0.011**[^1^](#t009fn001){ref-type="table-fn"}
  Total Number of Blinks                        5.0 (3.4)            7.9 (4.0)      **\<0.001**[^1^](#t009fn001){ref-type="table-fn"}
                                                **Number of eyes**                  
  Severe Meibomian Gland Atrophy                5 / 95               12 / 90        0.164[^2^](#t009fn002){ref-type="table-fn"}
  Present / Not Present                                                             
  Meibomian Gland Tortuosity                    74 / 26              57 / 45        **0.031**[^2^](#t009fn002){ref-type="table-fn"}
  Present/Not Present                                                               
  All Partial Blinks / Not All Partial Blinks   52 / 48              35 / 67        **0.033**[^2^](#t009fn002){ref-type="table-fn"}

^1^ Robust linear Regression with Huber-White standard error estimator clustered by Subject ID.

^2^ Robust logistic Regression with Huber-White standard error estimator clustered by Subject ID.

Discussion {#sec018}
==========

This cross-sectional study aimed to determine risk factors for severe Meibomian gland atrophy by accounting for both endogenous and exogenous factors and to investigate the potential downstream impact of severe Meibomian gland atrophy. [Fig 3](#pone.0185603.g003){ref-type="fig"} summarizes the study findings. Of the potential risk factors considered for this young adult population, HBC use was the only significant risk factor for severe Meibomian gland atrophy. When we considered downstream effects, we found that severe Meibomian gland atrophy was associated with thinner tear lipid layer, shorter FTBUT was statistically but not clinically significantly associated with thinner tear lipid layer, and neither FTBUT nor NITBUT were associated with symptoms.

![Summary of significant relationships based on final multivariable models between risk factors (arrow origin) and outcomes (arrowhead).\
SPEED = Subjective Patient Evaluation of Eye Dryness; NITBUT = Non-invasive Tear Breakup Time; FTBUT = Fluorescein Tear Breakup Time.](pone.0185603.g003){#pone.0185603.g003}

Since Meibomian glands are believed to be regulated by sex hormones \[[@pone.0185603.ref003],[@pone.0185603.ref027],[@pone.0185603.ref028]\], it is not surprising that HBCs can have a significant effect on Meibomian glands. HBCs act by decreasing androgen synthesis in the ovaries, adrenal glands, and peripheral tissues and reducing serum free testosterone levels by increasing sex hormone-binding globulin levels \[[@pone.0185603.ref029],[@pone.0185603.ref030]\]. In the Meibomian glands, androgens appear to modulate lipid production and gene expression, while estrogens antagonize the actions of androgens by suppressing lipid synthesis \[[@pone.0185603.ref031],[@pone.0185603.ref032]\]. While the relationship between HBC and Meibomian gland atrophy can be justified physiologically, other factors have also been linked to Meibomian gland atrophy. One is contact lens use, which is common among this young adult study population and has been shown, in some studies, to affect Meibomian gland atrophy \[[@pone.0185603.ref033],[@pone.0185603.ref034]\]. Other studies, however, have found inconclusive or no evidence of such a relationship \[[@pone.0185603.ref019],[@pone.0185603.ref035]\]. In the present study, duration of contact lens use alone was significantly associated with the presence of severe Meibomian gland atrophy, but it was no longer significant after controlling for HBC use. However, the small sample size of severe Meibomian gland atrophy does not allow proper analyses to determine the relative impact of contact lenses and HBC on Meibomian glands. Therefore, a larger, controlled study is warranted.

The relationship between severe Meibomian gland atrophy and thin tear lipid layer has been reported to be significant in other studies, despite differences in methodology \[[@pone.0185603.ref006]--[@pone.0185603.ref010]\]. In the present study, thinner tear lipid layer was significantly associated with greater years of contact lens use and complete blinking, but the relationships were not clinically significant. The use of HBC significantly affected the relationship between severe Meibomian gland atrophy and tear lipid layer thickness, such that females using HBC, regardless of Meibomian gland atrophy severity, had significantly thinner tear lipid layer than females not using HBC. To our knowledge, no study has reported the impact of HBC use on the relationship between Meibomian gland atrophy and tear lipid layer thickness.

The relationship between thinner tear lipid layer and shorter FTBUT was statistically significant, but the effect was too small to be detected clinically. NITBUT was not associated with tear lipid layer thickness. This relationship between tear-lipid thickness measured with the LipiView™ and tear film stability has been inconsistent in the literature \[[@pone.0185603.ref008],[@pone.0185603.ref010]\]. It is unclear if the lack of association with tear film stability is due to poor instrument accuracy or precision or if tear-lipid thickness is an insufficient predictor of tear film stability. In general, we expect tear film stability to increase with increasing tear-lipid thickness, but there are a few examples that do not completely agree with this general impression. First, a previous study reported that tear-lipid stability could be maintained over a wide range of tear-lipid thicknesses and that instability would more likely occur below a certain threshold of tear lipid layer thickness \[[@pone.0185603.ref036]\]. Another example involves a tear-lipid layer that is thick, on average, but varies greatly over the measurement area \[[@pone.0185603.ref037]\]. It has been shown that a thick tear-lipid film can be associated with unstable tear film or a thin tear-lipid film can be associated with a stable tear film \[[@pone.0185603.ref037]\]. Therefore, understanding meibum quality (biophysical properties and/or composition) is just as important as lipid layer thickness when evaluating the impact of tear lipid layer on tear film stability \[[@pone.0185603.ref037]--[@pone.0185603.ref039]\].

This current study did not confirm an association between ocular dryness symptoms measured with the SPEED questionnaire and tear film stability, as hypothesized. This lack of association is consistent with a previous study that used similar methods, despite controlling for potential confounders \[[@pone.0185603.ref040]\]. Instead, we found that symptoms of ocular dryness were associated with eye drop use, which is likely a bidirectional relationship.

When evaluating the differences between users and non-users of contact lenses, we found that symptoms (SPEED), NITBUT, blink pattern, Meibomian gland expressibility and presence of tortuous Meibomian glands were significantly different between the groups. This study did not find a difference in presence of severe Meibomian gland atrophy between the two groups, which supports previously published findings by Machalinska, et al.\[[@pone.0185603.ref035]\], and Pucker, et al.\[[@pone.0185603.ref019]\], but contradict findings reported by Arita, et al.\[[@pone.0185603.ref026]\] and Alghamdi, et al.\[[@pone.0185603.ref034]\]. The discrepancy among these studies may be attributed to study population differences, such as demographics (age, race, and gender distributions), diet, and environmental factors. With many potential factors that may impact the ocular surface, a well-controlled, prospective study would help to elucidate the potential impact of contact lenses on the Meibomian glands.

In addition to the results related to the main and secondary outcomes, two other points are worth discussing. The first is the discrepancy between the two measures of tear film stability, NITBUT and FTBUT, which are highly correlated but yielded different results in the study models. This discrepancy may be attributed to the obvious differences in methods; the instillation of a fluorescein drop on the ocular surface to measure FTBUT can perturb the tear lipid layer, which in turn can cause a disruption in tear film stability that would not otherwise be seen with the Placido-based NITBUT measurement \[[@pone.0185603.ref041]\]. Although FTBUT is inherently variable due to the uncontrolled drop volume and concentration applied, the non-automated NITBUT measurements rely on visual observation of Placido rings that can be difficult to interpret, thus causing significant variability in the measurement.

The other result worth noting relates to blinking pattern. Subjects with all partial blinks during the measurement period had a thicker average tear lipid layer and better tear film stability (FTBUT and NITBUT). One explanation may be that eyes which have a thick tear lipid layer may have less of an urge to blink completely, and those with a thinner tear lipid layer are more inclined to blink completely in order to increase or restore tear lipid layer thickness. Ousler, et al. reported that there were slightly more partial blinks (52.9%) among normal eyes than among dry eyes (50.96%) and that total contact time (lid-to-lid) was seven times longer in dry-eye subjects than normal subjects (0.565 versus 0.080 seconds, respectively; P\<0.001)\[[@pone.0185603.ref042]\]. While poor tear film can be the result of partial blinking tendencies in those individuals \[[@pone.0185603.ref043]--[@pone.0185603.ref046]\], we might consider that another group of individuals exist who are less inclined to blink completely due to the presence of a robust tear film. Another plausible explanation is that visual fixation on a light target in the LipiView® increases the tendency to blink partially. Several recent studies reported that reading and computer tasks increase the frequency of partial blinks \[[@pone.0185603.ref047]--[@pone.0185603.ref049]\], and it is possible that similar effects result with light fixation targets. It is unclear how such a task may impact those with healthier tear films differently, but if the general tendency is to blink partially and less frequently during these visual tasks, those with healthier tear films would likely tolerate those tendencies better than those with less robust tear films. Other possible reasons for discrepancies between the current study and previous findings on the relationship between blinking and tear lipid layer thickness may be attributed to differences in experimental setups, environmental conditions, and measurement algorithm (i.e., definition of partial blink vs. complete blink). While blinking results in this study were not captured under stringently controlled conditions, they are representative of data that would be collected by clinicians using the LipiView™ instrument on a healthy, young adult population.

This study was not without limitations. The young, healthy adult study population, limited the ability to assess age-related effects on the Meibomian glands reported by other studies \[[@pone.0185603.ref009],[@pone.0185603.ref016],[@pone.0185603.ref026]\]. While these results cannot necessarily be extended to the general population, they are useful for understanding the complex relationship that HBC has with the ocular surface in a population where its use is highly prevalent. Second, the main outcome of interest, severe Meibomian gland atrophy, was present in 17 of 202 eyes (8.4%) in this young population compared to 18% \[[@pone.0185603.ref015]\] and 43% \[[@pone.0185603.ref016]\] reported in older populations whose mean ages were 45 \[[@pone.0185603.ref015]\] and 57 \[[@pone.0185603.ref016]\] years, respectively. Although it is unclear if this current study accurately represents Meibomian gland atrophy distribution in the general population for this age group, these results are consistent with the expectation that the prevalence of severe Meibomian gland atrophy is higher in older age groups \[[@pone.0185603.ref009],[@pone.0185603.ref016],[@pone.0185603.ref026]\]. Third, this current study did not control for estrogen concentrations, type of progestin, diurnal or monthly hormonal variations, or the duration of HBC use, all of which may affect the relationships reported. Finally, the distribution of contact lens users among the female HBC groups was skewed and the sample size was small after stratification, making the analysis difficult to determine the independent effect of HBC and contact lens use on Meibomian gland structure and function.

In summary, HBC use may increase the odds for having severe Meibomian gland atrophy and affect the relationship between severe Meibomian gland atrophy and tear lipid layer thickness. Future studies with larger samples sizes are warranted to confirm these findings.
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